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Introduction
Kaposi's sarcoma-associated herpes virus (KSHV) complement control protein (KCP) acts as an endogenous complement inhibitor expressed from the viral genome. KCP is encoded by ORF4 within the KSHV genome and consists of four complement control protein (CCP) domains, which are typical for proteins controlling the complement system [1] . We have shown previously that KCP interferes with initial stages of complement cascade activation by enhancing dissociation of C3 convertases and acting as cofactor to serine proteinase factor I in degradation of activated complement factors C3b and C4b (reviewed in [2] ). Being not only a surface antigen but also a viral protector against the host immune response, KCP emerges as a unique potential target for immunotherapy. Although the role of KCP in pathogenesis has not been examined yet due to the lack of an animal model of infection, one potentially important question is whether infected individuals produce specific antibodies directed against KCP protein and whether this fact has any further consequences for the disease progression. While analyzing sera from 22 patients suffering from classical or HIV-associated Kaposi's sarcoma (KS) and KSHV-related lymphoproliferative diseases such as primary effusion lymphoma (PEL) or solid KSHV-related lymphoma (SLY) we found anti-KCP antibodies in seven of the patients [3] . Due to limited number of patients and limited amounts of sera we could perform neither a reliable statistical analysis for individual diseases nor functional assays. Despite these limitations, we observed that anti-KCP antibodies appear more frequently in patients suffering from KSHV-related lymphomas than classical or HIV-associated KS and mostly in those with high titer of KSHV anti-lytic antibodies. The latter is in agreement with the fact that KCP belongs to the group of lytic proteins of KSHV [1] . We also analyzed immune responses against the VCA antigen of Epstein-Barr virus, which is expected to be present in 90% of adults [4] and we did not observe any difference between VCA response in HIV positive and HIV negative patients. Therefore, the lower percentage of anti-KCP antibodies in HIV positive KS patients did not stem from a general inability of antibody production due to immunosuppression. Finally, we showed that anti-KCP antibodies increase complement deposition on the surface of cells expressing KCP. However, it was not possible to determine if the observed effect was due to functional neutralization of KCP or additional deposition of antibodies and ensuing complement activation on the cell surface.
Remaining questions, which can only be answered based on the study of larger numbers of patients are: i) whether previously observed higher prevalence of anti-KCP antibodies in KSHV-related lymphomas patients is reproducible, ii) are there any differences in prevalence of anti-KCP antibodies between particular KSHV-related diseases, iii) are anti-KCP antibodies able to protect individuals already exposed to KSHV from disease, iv) if the clinical stage or disease progression is reflected by presence of anti-KCP antibodies and v) if anti-KCP antibodies are capable of blocking the function of KCP. To investigate these issues, we analyzed three groups of patients suffering from KSHV-related diseases or healthy individuals who only showed detectable immune response against KSHV antigens. Blood samples of the two patients' groups were collected in Italy, a region where KS occurs with higher frequency compared to the rest of Europe [5] . Additionally, the second Italian group included patients suffering only from classical KS, who have been classified as slow or fast progressing [6] . The third group included a population-based sample of healthy individuals from northern Sweden, who were positive for anti-lytic or anti-latent KSHV antigens [7] . Since the incidence of classical KS in northern Sweden is estimated to be four-fold lower than in Italy [8] , we wanted to check whether these individuals have elevated levels of anti-KCP antibodies compared to previously studied groups of Italian patients. This could suggest possible role of anti-KCP response in protection from KS development.
Methods

Patients
The first group of patients suffering from KSHV-related diseases included 9 patients with Diagnostic criteria for these patients are described in [9] .
The second group included 35 patients suffering from classical KS, partially described in the study of Mancuso et al. [6] . These individuals were stratified into subgroups of patients with anti-latent and anti-lytic KSHV antibody titer estimated by immunofluorescence assay. All the methods used to obtain clinical data are described in the original study [6] .
The third group of patients was chosen from 520 individuals from Västerbotten county in northern Sweden, previously classified for the KSHV seroprevalence [7] . Out of a total of 520 serum samples available we chose 75, which were positive for anti-lytic or anti-latent KSHV antigens. This group is subsequently called healthy controls.
Since data obtained from groups I and III were used to compare a prevalence of anti-KCP antibodies, in particular KSHV-related diseases and controls, we examined if patients suffering from particular disease and healthy controls were matched concerning their age and gender (Table 1) 
Detection of anti-KCP antibodies in patients' sera
Anti-KCP antibodies were detected as described in [3] . Briefly, CHO cells transfected with cDNA coding for KCP cloned into pKevin or empty vector (mock) were incubated with analyzed, heat-inactivated patient serum at the dilution 1:50, followed by detection of bound IgG with specific antibodies (Dako Cytomation) and FITC-conjugated secondary antibody (Dako Cytomation). Cells were analyzed by flow cytometry (Partec CyFlow Space) and the results were expressed as mean fluorescence intensity (MFI) ratios between KCP and mock-transfected cells.
Flow cytometry-based method is superior to ELISA, since it analyzes KCP in its physiological conformation on the cell surface and excludes the problem of possible antigen masking/reorientation due to immobilization on the plate surface (discussed in [3] ). The performance of the assay is characterized by the values of 8.89% for intra-assay coefficient of variation (CV) and 11.08% for inter-assay CV.
Purification of natural KCP antibodies from patient's serum
Total immunoglobulin fraction was purified from the serum of the patient who showed the highest level of anti-KCP antibodies in order to test if these antibodies could block function of KCP. Ten ml of this serum as well as normal human serum (control) were incubated with 0. 
C3b/C4b degradation assay
Factor I degrades activated complement factors C3b and C4b only in the presence of appropriate cofactor such as KCP [10] . To assess the ability of patient's anti-KCP antibodies to neutralize the cofactor activity of KCP, we incubated purified KCP (0.05 µg/ml), FI (0.02 µg/ml for C3b and 0.06 µg/ml for C4b), trace amounts of 125 I -labelled C3b or C4b and purified immunoglobulin fraction from patient or control serum (3 mg/ml) for 1.5h at 37 °C. Afterwards, 
Ethical consideration
Samples from healthy controls and patients were obtained with the informed consent and the study was approved by the ethics committees and followed the Declaration of Helsinki.
Results and discussion
Demographic distribution of individuals from groups I and III.
Classical KS patients were significantly older than patients with PEL (P<0.05), HIV+KS (P<0.01) and healthy control subgroup (P<0.01), according to Kruskal-Wallis test. These differences remained even when MCD, PEL and SLY patients were pooled as a KSHV-related lymphoma subgroup but were not statistically significant when KS patients were considered as uniform subgroup. Regarding gender, women were underrepresented to a varying degree in all patient groups but not in healthy controls. Therefore, we included additional analyses of anti-KCP antibodies presence restricted to men from groups I and III. More advanced age of classical KS patients in relation to other KSHV-related diseases as well as higher incidence of KSHV infection in men than woman are phenomena generally recognized for these diseases [11] [12] [13] .
Anti KCP antibodies occur more frequently in patients with KSHV-related lymphomas than in patients with KS.
We analyzed the prevalence of anti-KCP antibodies in the first group, which included 75 (Fig.1b) . The same level of significance was reached when HIV+KS and HIV-KS were combined into one KS subgroup (Fig. 1c) . When all patients with diagnosed KSHV-related disease were compared to healthy group, the Mann-Whitney two-tailed test returned the value of 0.0548, which was close to the level of significance and 95% CI of 1.28-2.16 (diagnosed group) vs. 1.006-1.16 (healthy group), respectively (Fig. 1d) . Similar statistical analyses performed exclusively on male subjects returned the same statistically relevant differences except for the MCD and HIV-KS pair (Fig. 1a) KCP antigen is not a factor protecting from disease development, but is rather elevated at the time of active disease.
Anti-KCP antibodies correlate with anti-lytic KSHV antibodies in classical KS but not with clinical stage, disease progression and viral load in body fluids.
We analyzed anti-KCP antibodies in patients with classical (HIV-) KS. Patients from this group were additionally classified into subgroups depending on slow (A) or fast (B) disease progression [6] , clinical stage (I-IV, according to criteria described in [16] ) and viral load in blood, serum and saliva [6] .
Disease progression did not correlate with the presence of anti-KCP antibodies (Fig. 2a) . Values in these two populations were not distributed normally and medians were 1.375 (0.6459-3.542) and 1.57 (0.907-4.041) for slow and fast progressing KS, respectively. Mann-Whitney U test returned the value of 0.3571 (not significant). Progression in clinical stage of KS resulted in higher median values of anti-KCP antibody prevalence (1.33; 1.38; 1.57 and 2.945 for stages 1-4, respectively). However, a Kruskal-Wallis test showed a general P value of 0.059. It is likely that inclusion of more stage IV patients would result in statistical significance (Fig. 2b) . Next we correlated the anti-lytic and anti-latent antibody titers with anti-KCP presence. It is important to note, that this group of patients had much higher titers of lytic and latent KSHV antibodies, comparing to those from our pilot study [3] and the healthy group [7] . In the first study, 54.5 % of patients had a titer of anti-lytic KSHV antibodies lower than 1:640 and 50 % of patients had similar titers for anti-latent antibodies. In the healthy group these numbers were 96 % and 98. Further analysis showed no correlation with blood viral load (r= -0.061, P= 0.7252), serum viral load (r= -0.0309, P= 0.86) and saliva viral load (r= -0.091, P= 0.6028). Previous study of this patient group showed higher titer of anti-lytic KSHV antibodies in fast (type B) vs slow KS progressors [6] . Additionally, a higher viral load was observed in blood and serum in patients with fast evolution of the disease while the opposite was found for viral saliva load [6] .
Comparing our current results of anti-KCP antibodies with these findings one can conclude that KCP-specific antibodies, although strongly correlated with anti-lytic KSHV antibodies, are not enriched in the group of fast progressors of KS. Also, they do not preferentially appear in those patients with higher blood and serum viral load. This shows that an anti-KCP immune response does not simply reflect disease progression with concomitant increase of lytic KSHV antigens, as these are present in the same degree in slow-progressing patients. On the contrary, it is possible that at least some individuals with high anti-lytic KSHV antibody titer were turned to slow KS progressors because of the presence of KCP-specific antibody.
anti-KCP antibodies isolated from patient serum block KCP function.
Next we tested whether antibodies against KCP may block the complement inhibitory function of KCP. We obtained substantial amount of serum from the patient who had the highest titer of anti-KCP antibodies in order to purify the immunoglobulin fraction. Purified immunoglobulins were then used as an inhibitor of KCP in C3b and C4b degradation assays. In both experiments we observed strong inhibition of KCP cofactor activity, which could not be observed with immunoglobulins isolated from healthy control (Fig. 3 ).
Taken together, we showed that prevalence of anti-KCP antibodies in classical KS patients does not follow the prediction based on other correlations described for the same group, i.e. since fast progression of KS correlated with high anti-lytic KSHV antibody titer, and high anti-KCP antibody levels correlated with high anti-lytic KSHV antibody titer, we expected to find higher anti-KCP antibody level in fast KS progressors. Our opposite finding suggests a specific role of anti-KCP antibodies in regulation of KS progression and such a role may be based on blocking of the KCP complement inhibitory function by specific antibodies developed by patients.
[ Representative radiograms (out of three independent experiments) of degradation assay of complement proteins C3b (a) and C4b (b). Immunoglobulin fraction purified from serum of
